Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H29NO4 |
| Molecular Weight | 395.4914 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C(OCC)C=C(CC2=NC=CC3=CC(OCC)=C(OCC)C=C23)C=C1
InChI
InChIKey=ZOWYFYXTIWQBEP-UHFFFAOYSA-N
InChI=1S/C24H29NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-12,14-16H,5-8,13H2,1-4H3
| Molecular Formula | C24H29NO4 |
| Molecular Weight | 395.4914 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
In the US, Ethaverine is a member of the drug class peripheral vasodilators. It’s an alkaloid prepared synthetically from opium with no narcotic properties. Directly relaxes all smooth muscles, especially when they have been spasmodically contracted. Action is especially pronounced when spasm is present on coronary, cerebral, pulmonary, and peripheral arteries. Acts directly on myocardium like quinidine; depresses conduction and irritability, and prolongs refractory period. Primarily for peripheral and cerebral vascular insufficiency associated with arterial spasm; also a smooth muscle spasmolytic in spastic conditions of the GI and GU tracts. Adverse Effects ( 1%) CNS: Vertigo, headache, drowsiness. CV: Hypotension, arrhythmias. GI: Nausea, anorexia, abdominal distress, dry throat. Other: Malaise, flushing, sweating, lassitude, respiratory depression. Ethaverine may decrease levodopa effectiveness; morphine may antagonize smooth muscle relaxation effect of ethaverine.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095229 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1658607 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A novel flow cytometric high throughput assay for a systematic study on molecular mechanisms underlying T cell receptor-mediated integrin activation. | 2009-06-25 |
|
| Stereoselective total synthesis of bioactive styryllactones (+)-goniofufurone, (+)7-epi-goniofufurone, (+)-goniopypyrone, (+)-goniotriol, (+)-altholactone, and (-)-etharvensin. | 2008-01-04 |
|
| Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and anti-HIV agents. | 2001-11 |
|
| Inhibitory effects of ethaverine, a homologue of papaverine, on monoamine oxidase activity in mouse brain. | 2001-07 |
|
| Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei. | 2001-04-13 |
|
| Inhibitory effects of ethaverine, a homologue of papaverine, on dopamine content in PC12 cells. | 2001-01 |
|
| Tumor- and drug-induced cutaneous neuro-phospholipidosis. | 1975 |
Patents
Sample Use Guides
for adult: 100 mg t.i.d., may increase up to 200 mg t.i.d.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1658607
0.3-30 microM ethaverine on either side of the dihydropyridine-sensitive, L-type calcium channel from porcine cardiac muscle caused a reduction in the channel open probability (EC50 approximately 1 microM), with the higher concentrations inhibiting channel activity almost completely
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:18 GMT 2025
by
admin
on
Mon Mar 31 17:54:18 GMT 2025
|
| Record UNII |
2H2HC19DYZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3280
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
C73332
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL1555736
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
1077
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
100000082615
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
207-633-3
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
299
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
DTXSID3023009
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
2H2HC19DYZ
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
486-47-5
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
24464
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB07272MIG
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | |||
|
m5053
Created by
admin on Mon Mar 31 17:54:18 GMT 2025 , Edited by admin on Mon Mar 31 17:54:18 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |